U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H25N3O5S.CO3.2Na
Molecular Weight 489.451
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEROPENEM SODIUM CARBONATE

SMILES

[Na+].[Na+].[O-]C([O-])=O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O

InChI

InChIKey=SGVRKQURIVADFJ-OBZXMJSBSA-L
InChI=1S/C17H25N3O5S.CH2O3.2Na/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;2-1(3)4;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);(H2,2,3,4);;/q;;2*+1/p-2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H25N3O5S
Molecular Weight 383.463
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula CO3
Molecular Weight 60.0089
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |

Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.

CNS Activity

Originator

Approval Year

1996
224
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

1996
Primary
Approved
8583
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

1996
Curative
Approved
8583
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.9 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
20 mg/kg 3 times / day other, intravenous
dose: 20 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
61 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
30 mg/kg 3 times / day other, intravenous
dose: 30 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
445 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
20 mg/kg 3 times / day other, intravenous
dose: 20 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
444 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
30 mg/kg 3 times / day other, intravenous
dose: 30 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.33 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
20 mg/kg 3 times / day other, intravenous
dose: 20 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
1.58 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf
30 mg/kg 3 times / day other, intravenous
dose: 30 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
MEROPENEM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B1-01460
http://www.3bsc.com/index/pro_info.php?id=21672
3B Scientific (Wuhan) Corp
3B2-0044
http://www.3bsc.com/index/pro_info.php?id=19400
3B Scientific (Wuhan) Corp
3B2-1156
http://www.3bsc.com/index/pro_info.php?id=54872
Aaron Chemicals
AR00397K
http://www.aaronchem.com/96036-03-2
Achemo Scientific Limited
AC-13275
http://www.achemo.com/search/?Keyword= 96036-03-2
Achemtek
0101-001564
http://www.achemtek.com/96036-03-2
Acorn PharmaTech
ACN-048182
http://www.acornpharmatech.com/
Adooq BioScience
A10569
https://www.adooq.com/meropenem.html
AEchem Scientific Corp., USA
AE1-006420
http://www.aechemsc.com/info_products/AE1-006420.php
AHH Chemical co.,ltd
API-1041
http://www.ahhchemical.com/product/API-1041.html
AHH Chemical co.,ltd
MT-53511
http://www.ahhchemical.com/product/MT-53511.html
AK Scientific, Inc. (AKSCI)
J10087
http://www.aksci.com/item_detail.php?cat=J10087
Ambeed
A647306
https://www.ambeed.com/products/96036-03-2.html
ApexBio Technology
A5124
http://www.apexbt.com/meropenem-22012.html
AstaTech, Inc.
45000
http://www.astatechinc.com/CPSResult.php?CRNO=1382
Aurum Pharmatech LLC
S-3680
http://www.Aurumpharmatech.com/Product/ProductDetails/S_3680
AvaChem Scientific
1716
http://www.avachem.com/productSearch.asp?1716
BioSynth
M-2780
https://www.biosynth.com/products/biochemistry/culture-media-additives/products/M-2780.html
BLD Pharm
BD23263
http://www.bldpharm.com/products/96036-03-2.html
Capot Chemical
17275
http://www.capotchem.com/en/17275.htm
Capot Chemical
PubChem17275
http://www.capotchem.com/en/17275.htm
Chem Scene
CS-1865
http://www.chemscene.com/96036-03-2.html
ChemMol
2100052
http://www.chemmol.com/chemmol/2100052.html
ChemMol
97602823
http://www.chemmol.com/chemmol/97602823.html
Chemspace
CSSB00020615435
https://chem-space.com/CSSB00020615435
Chiralblock Biosciences
CB11530
http://www.chiralblock.com/products/96036-03-2.html
Clearsynth
CS-M-58087
http://www.clearsynth.com/en/CSM58087.html
CSNpharm
CSN13108
https://www.csnpharm.com/products/meropenem.html
DC Chemicals
DCAPI1395
http://www.dcchemicals.com//product_show-Meropenem.html
eNovation Chemicals
D518319
https://www.enovationchem.com/ProductDetails.asp?ProductID=D518319
Glentham Life Sciences
GP7412
http://www.glentham.com/products/product/GP7412/
Hairui
HR124915
http://www.hairuichem.com/en/product/119478-56-7.html
Hairui
HR127380
http://www.hairuichem.com/en/product/96036-03-2.html
Lab Network
LN00174071
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00174071
Matrix Scientific
75811
https://www.matrixscientific.com/075811.html
MedChem Express
HY-13678
https://www.medchemexpress.com/meropenem.html
MuseChem
A000590
https://www.musechem.com/product/A000590.html
Oakwood
36531
http://www.oakwoodchemical.com/p-31256-036531.aspx
Oakwood
M05727
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130064&ExtHyperLink=1
OChem
7522
http://www.ocheminc.com/index.php?act=psearch&pid=036M032
Sinfoo Biotech
S061047
http://www.sinfoobiotech.com/product/1064450
Smolecule
S535012
http://www.smolecule.com/products/s535012
Smolecule
S795550
https://www.smolecule.com/products/s795550
TCI (Tokyo Chemical Industry)
M2279
http://www.tcichemicals.com/eshop/en/us/commodity/M2279/index.html
THE BioTek
bt-274921
https://www.thebiotek.com/product/inhibitors/bt-274921
THE BioTek
bt-289487
https://www.thebiotek.com/product/others/bt-289487
PubMed

PubMed

TitleDatePubMed
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities.
2002-03-15
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
2002-03
Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.
2002-02
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
2002-02
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units.
2002-02
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
2002-02
Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains.
2002-02
Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium.
2002-01-05
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.
2002-01
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.
2002-01
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.
2002-01
[The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem].
2001-12-19
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001-12-14
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
2001-12
Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999.
2001-12
Empirical monotherapy with meropenem in serious bacterial infections in children.
2001-12
Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.
2001-12
Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies.
2001-12
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
2001-12
Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).
2001-12
MYSTIC program: summary of European data from 1997 to 2000.
2001-12
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).
2001-12
Determining the value of antimicrobial surveillance programs.
2001-12
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
2001-12
In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.
2001-12
National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network.
2001-11-01
[A case of eosinophilic pneumonia possibly due to ifenprodil].
2001-11
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
2001-11
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
2001-11
In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains.
2001-11
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy.
2001-10
Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain.
2001-10
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans.
2001-09-19
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
2001-09-03
[A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
2001-09
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures].
2001-09
[Pyogenic sacroiliitis in pregnancy].
2001-09
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
2001-09
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
2001-09
Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.
2001-09
Isolation and culture of airway epithelial cells from chronically infected human lungs.
2001-09
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.
2001-09
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp].
2001-08
Use of broad spectrum antibiotics in six non-university Swiss hospitals.
2001-07-28
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
2001-07
Ertapenem: a new carbapenem.
2001-06
Antibiotic persistence: the role of spontaneous DNA repair response.
2001
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
2001
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
2001
[Antibiotic therapy of cystic fibrosis in children].
2001
Patents

Patents

06022885
5
08097719
3
08841444
3
JP2002520419A
58
JP2002541233A
406
JP2003515526A
470
JP2007530485A
10
JP2008543916A
10
JP2009143808A
3
JP2011155929A
3
JP2011241212A
3
JP2011510954A
147
JP2011528275A
456
JP5373390B2
3
JPH061718A
3
JPH06340529A
3

Sample Use Guides

In Vivo Use Guide
Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended. Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: Meropenem was 4-64 times more active than imipenem against gram-negatives, including Enterobacteriaceae organisms, Pseudomonas aeruginosa, Burkholderia cepacia, Neisseria meningiditis, and Haemophilus influenzae. Imipenem was up to 2-4 times more active than meropenem against some gram-positive cocci, including Enterococcus faecalis. Meropenem, unlike imipenem or ceftazidime, was bactericidal for all strains of Enterobacteriaceae, P. aeruginosa, and gram-positive cocci tested at < or = 8 times the MIC.
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 10:33:24 GMT 2025
Edited
by admin
on Wed Apr 02 10:33:24 GMT 2025
Record UNII
6LJ3NWM7AZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Meropenem sodium carbonate [WHO-DD]
Preferred Name English
MEROPENEM SODIUM CARBONATE
Common Name English
Code System Code Type Description
FDA UNII
6LJ3NWM7AZ
Created by admin on Wed Apr 02 10:33:24 GMT 2025 , Edited by admin on Wed Apr 02 10:33:24 GMT 2025
PRIMARY
PUBCHEM
127258876
Created by admin on Wed Apr 02 10:33:24 GMT 2025 , Edited by admin on Wed Apr 02 10:33:24 GMT 2025
PRIMARY
SMS_ID
300000017633
Created by admin on Wed Apr 02 10:33:24 GMT 2025 , Edited by admin on Wed Apr 02 10:33:24 GMT 2025
PRIMARY
Related Record Type Details
Structure of MEROPENEM ANHYDROUS
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966